晚期NSCLC免疫一线治疗策略PPT课件下载推荐.pptx
- 文档编号:13189429
- 上传时间:2022-10-08
- 格式:PPTX
- 页数:32
- 大小:3.77MB
晚期NSCLC免疫一线治疗策略PPT课件下载推荐.pptx
《晚期NSCLC免疫一线治疗策略PPT课件下载推荐.pptx》由会员分享,可在线阅读,更多相关《晚期NSCLC免疫一线治疗策略PPT课件下载推荐.pptx(32页珍藏版)》请在冰豆网上搜索。
squamous,Non-squamous,Squamous,AllPD-L1,AllPD-L1,Monotherapy,ChemotherapyCombinations,AntiangiogenicCombanations,CIT+CIT,Non-squamous&
squamous,AllPD-L1,PD-L11%,NCCNClinicalPracticeGuidelinesinOncology(NCCNGuidelines)Non-SmallCellLungCancerVersion4P.l2a0n2ch0ardD,etal.AnnOncol.2018Oct1;
29(Suppl4):
iv192-iv237.GUIDELINESOFCHINESESOCIETYOFCLINICALONCOLOGY(CSCO)NON-SMALLCELLLUNGCANCER2020,用药方案,双,药,帕博利珠单抗vs.含铂双,药,泰圣奇vs.顺铂/卡铂+培美曲塞/吉西他,滨,TPS50%:
26.3vs.14.2个,TPS50%:
20vHsR.12.2个,TC3或IC3,W20T.2:
vs.13.1个,月HR,P0=.509.0106,月HR0.65P=0.00110.3vs.6.0,OSPFS(月)ORR(%),45vs.28,月P0=.609.0037.1vs.6.4(TPS50%)40vs.32(TPS50%),TPS50%118(76.6)vs.135(90.0)48(31.2)vs.80(53.3)20(13.2)vs.1(0.7),8.1vs.5.0(TC3或IC3)38.3vs.28.6(TC3或IC3)173(60.5)vs.224(85.2)37(12.9)vs.116(44.1)19(6.6)vs4(1.5)*,不良事件n(%),任意级别TRAE3级TRAE3级irAE,399(63)vs.,151533(179.08)vs.252(41)51(8.0%)vs.9(1.5),NSCLC一线免疫单药研究,用药方案,帕博利珠单抗vs.含铂双药,ABCPvsACPvs,BCP,Nivolumab3mg/kgQ2W+,Ipilimumab1mg/kgQ6W(),4cycles,(4cycles),moQ3W,ITT-WT:
19.5vs14.7vs.Che,Nivolumab360mgQ3W+,Ipilimumab1mg,vs.CheQm6oWQ(3W2cy(cl4e)cycles),P0.01HR0.80,TWCT1/:
2/3或IC1/2/34-vs,1622.5vs.24.,TC0和IC0-WT:
14.8v16s.9.vs.14.1,OS,HRP0.0,ITT:
22vs.10.7个月PD,0.56%:
NR1,10.1,PDL115-409%:
21.18v2s.v1s,PDL11%17.2vs10.2,HRP0.007,PDL11%17.1vs.14.9,PD0.7917.2vs.12.2,L11%HR0.62,HR,ITT人群15.6vs.10.9,0.66,PD15.8vs10.9HR0.64,L11%,PD16.8vs9.8HR0.62,NSQL1171v%s.11.9,HR0.69SQ14.5vs.9.1HR0.62,PFS,9.0vs4.9,8.3vs6.8,5.1vs.5.6,NSCLC一线免疫联合用药研究,1)GhandiL,etal.NEJM.16April2018.2)GadgeelS,etal.PresentedatASCO2019.Abstract9013.3)Rodriguez-AbreuD.PresentedatASCO2020.Abstract9582.4)Paz-AresL,etal.PresentedatASCO2018.Abstract105.5)Paz-Ares,etal.NEnglJMed2018;
379:
2040-2051.6)Paz-AresL,etal.PresentedatESMO2019.AbstractLBA82.7)PetersS,etal.PresentedatESMO2019.AbstractLBA4.8)HellmanMet,al.NEJM.28Sept2019.9)RamalingamS,etal.PresentedatASCO2020.Abstract9500.10)ReckM,etal.PresentedatASCO2020.Abstract9501.,一线非小细胞肺癌主要临床研究数据比较(2020ASCO摘要公布),IMpower150:
Phase3studyofACPorABCPvsBCPinchemotherapy-naivepatientswithmetastaticnon-squamousNSCLC,FedericoCappuzzo.2020ASCOAbstract9587.,Co-primaryendpoints:
PFSintheITT-WTpopulationPFSintheTeff-highWTpopulationOSintheWTpopulation.,PFSandPSintheITTpopulationIndependentreviewfacilityassessedPFSintheWTpopulationInvestigator-assessedPFSinthePD-L1expressionsubgroupsintheWTpopulationORRandDORintheWTpopulationSafetyintheITTpopulation,Atezolizumab+carboplatinc+paclitaxel(ACP)4or6cycles,Atezolizumab+bevacizumab+carboplatinpacl+itaxel(ABCP),Atezolizumab,Maintenancetherapy(nocrossoverpermitted),Bevacizumab+carboplatin+paclitaxel(BCP)4or6cyclesKeysecondaryendpoints,Atezolizumabb+evacizumab,Bevacizumab,TreatedwithatezolizumabuntilPDperRECIST1.1orlossofclinicalbenefitand/orTreatedwithbevacizumabuntilPDperRECIST1.1,Survivalup,StageIVorrecurrentmetastaticnon-squamousNSCLCChemotherapynaiveTumortissueforbioamvarilkaebrletestingAnyPD-L1IHCstatusStratificationfactors:
SexPD-L1IHCexpressionLivermetastasesN=1202,R,1:
1:
1,IMpower150demonstratedstatisticallysignificantandcmlienaicnainllgyfulimprovementswithABCPvsBCPinPFSandOS,SocinskiMA,etal.NEnglJMed.2018Jun14;
378(24)2288-2301.,Investigator-AssessedPFSintheWTPopulation,OSintheWTPopulation,IMpower150:
ExploratoryAnalysisofBrainMetastasesDevelopment,Thebevacizumab-containingarmsofABCPandBCPhadcomparable,lowerratesofnewbrainlesiondevelopmentonstudyAtrendtowarddelayeddevelopmentofnewbrainlesionswasobservedwithABCPNonewsafetysignalswereobservedinthisexploratoryanalysisRateofNewBrainLesionsintheITTPopulationTTDofNewBrainLesionsintheITTPopulation,Thisreportfocusesonexploratoryanalyses,includingrateandtimetodevelopment(TTD)ofnewbrainmetastasesintheITTpopulation,regardlessofthepresenceofbrainmetastasesatbaseline,aswellassafetyinpatientswithandwithoutbrainmetastasesFedericoCappuzzo.2020ASCOAbstract9587.,HR=0.68,11.90%,7.00%,18%16%14%12%,IMpower150:
Exploratoryefficacyanalysisinpatientswithbulkydisease*,ExploratoryefficacyanalysesincludedPFS,OS,ORR,timetoresponse(TTR)inthesesubgroups;
safetywasalsoassessed.OutcomesarereportedforpatientsenrolledintheABCPvsBCP,arms.,*patientswithhightumorburdenorlargesizeRobertJotte.2020ASCO,Withaminimumfollow-upof32.4moths(datacutoff:
Sep13,2019),ABCPshowedimprovedOS,PFSandORRvsBCPinpatientswithhighandlowdiseaseburden.HighdiseaseburdendidnotimpactTTR.ThesafetyprofileofABCPwascomparablebetweenITT-WT(noEGFRorALKalterations)patientsandhighdiseaseburdensubgroups.,CheckMate227Part1:
Three-yearupdateo
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 晚期 NSCLC 免疫 一线 治疗 策略